Current Report Filing (8-k)
August 25 2022 - 07:47AM
Edgar (US Regulatory)
0001850119 false 0001850119 2022-08-25
2022-08-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 25, 2022
Century Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40498 |
|
84-2040295 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
3675 Market Street
Philadelphia,
Pennsylvania
|
|
19104 |
(Address of principal executive
offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (267)
817-5790
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
¨ |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each
Class |
|
Trading Symbol |
|
Name of Exchange on Which
Registered |
Common Stock, par value $0.0001 per share |
|
IPSC |
|
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
On August 25, 2022, Century Therapeutics, Inc. (the
“Company”) issued a
press release announcing the U.S. Food and Drug Administration
notified the Company that its ELiPSE-1 study may proceed to assess
CNTY-101 in patients with relapsed or refractory CD19 positive
B-cell malignancies. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
Item
9.01 |
Financial Statements and Exhibits |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
CENTURY
THERAPEUTICS, INC. |
|
|
|
|
By: |
/s/
Osvaldo Flores, Ph.D. |
|
Name: |
Osvaldo
Flores, Ph.D. |
|
Title: |
President
and Chief Executive Officer |
Date: August 25, 2022
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Apr 2023 to May 2023
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From May 2022 to May 2023